Skip to main content
Erschienen in: InFo Neurologie + Psychiatrie 9/2016

26.09.2016 | Zytostatische Therapie | zertifizierte fortbildung

Neuroonkologie

Meningeosis neoplastica

verfasst von: Prof. Dr. med. Michael Platten, Dr. med. Sarah Löw, Prof. Dr. med. Wolfgang Wick

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Als Meningeosis neoplastica (MN) wird die Ausbreitung von Tumorzellen im Subarachnoidalraum bezeichnet. Wenngleich sie eine interdisziplinär zu therapierende Erkrankung ist, spielt die Neurologie bei Diagnose und Behandlung der MN eine zentrale Rolle. Die MN ist in der Regel Ausdruck einer fortgeschrittenen Tumorerkrankung. Unbehandelt ist die Prognose auf sechs bis acht Wochen begrenzt, mit multimodaler Therapie beträgt sie zwei bis acht Monate [1].
Literatur
1.
Zurück zum Zitat Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49(4):759–72. PubMed PMID: 6895713.CrossRefPubMed Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49(4):759–72. PubMed PMID: 6895713.CrossRefPubMed
2.
Zurück zum Zitat Jaeckle KA. Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment. Semin Oncol. 2006;33(3):312–23. doi: 10.1053/j.seminoncol.2006.04.016. PubMed PMID: 16769420.CrossRefPubMed Jaeckle KA. Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment. Semin Oncol. 2006;33(3):312–23. doi: 10.1053/j.seminoncol.2006.04.016. PubMed PMID: 16769420.CrossRefPubMed
3.
Zurück zum Zitat Chamberlain MC. Neoplastic meningitis. Oncologist. 2008;13(9):967–77. doi: 10.1634/theoncologist.2008-0138. PubMed PMID: 18776058.CrossRefPubMed Chamberlain MC. Neoplastic meningitis. Oncologist. 2008;13(9):967–77. doi: 10.1634/theoncologist.2008-0138. PubMed PMID: 18776058.CrossRefPubMed
4.
Zurück zum Zitat Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979;29(10):1369–75. PubMed PMID: 573381.CrossRefPubMed Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979;29(10):1369–75. PubMed PMID: 573381.CrossRefPubMed
5.
Zurück zum Zitat Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int. 2013;4(Suppl 4):S265–88. doi: 10.4103/2152-7806.111304. PubMed PMID: 23717798; PubMed Central PMCID: PMCPMC3656567.PubMedPubMedCentral Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int. 2013;4(Suppl 4):S265–88. doi: 10.4103/2152-7806.111304. PubMed PMID: 23717798; PubMed Central PMCID: PMCPMC3656567.PubMedPubMedCentral
6.
Zurück zum Zitat Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer. 2004;101(4):810–6. doi: 10.1002/cncr.20418. PubMed PMID: 15305414.CrossRefPubMed Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer. 2004;101(4):810–6. doi: 10.1002/cncr.20418. PubMed PMID: 15305414.CrossRefPubMed
7.
Zurück zum Zitat Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol. 2012;159(1):39–49. doi: 10.1111/j.1365-2141.2012.09247.x. PubMed PMID: 22849793.CrossRefPubMed Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol. 2012;159(1):39–49. doi: 10.1111/j.1365-2141.2012.09247.x. PubMed PMID: 22849793.CrossRefPubMed
8.
Zurück zum Zitat Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25–32. doi: 10.1002/cncr.22381. PubMed PMID: 17146782.CrossRefPubMed Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25–32. doi: 10.1002/cncr.22381. PubMed PMID: 17146782.CrossRefPubMed
9.
Zurück zum Zitat DeAngelis LM, Mandell LR, Thaler HT, Kimmel DW, Galicich JH, Fuks Z, et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery. 1989;24(6):798–805. PubMed PMID: 2473409.CrossRefPubMed DeAngelis LM, Mandell LR, Thaler HT, Kimmel DW, Galicich JH, Fuks Z, et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery. 1989;24(6):798–805. PubMed PMID: 2473409.CrossRefPubMed
10.
Zurück zum Zitat van Oostenbrugge RJ, Twijnstra A. Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology. 1999;53(2):382–5. PubMed PMID: 10430430.CrossRefPubMed van Oostenbrugge RJ, Twijnstra A. Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology. 1999;53(2):382–5. PubMed PMID: 10430430.CrossRefPubMed
11.
Zurück zum Zitat Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol. 1996;53(7):626–32. PubMed PMID: 8929170.CrossRefPubMed Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol. 1996;53(7):626–32. PubMed PMID: 8929170.CrossRefPubMed
12.
Zurück zum Zitat van Oostenbrugge RJ, Hopman AH, Arends JW, Ramaekers FC, Twijnstra A. Treatment of leptomeningeal metastases evaluated by interphase cytogenetics. J Clin Oncol. 2000;18(10):2053–8. PubMed PMID: 10811670.PubMed van Oostenbrugge RJ, Hopman AH, Arends JW, Ramaekers FC, Twijnstra A. Treatment of leptomeningeal metastases evaluated by interphase cytogenetics. J Clin Oncol. 2000;18(10):2053–8. PubMed PMID: 10811670.PubMed
13.
Zurück zum Zitat Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Annals of neurology. 1995;38(1):51–7. doi: 10.1002/ana.410380111. PubMed PMID: 7611725.CrossRefPubMed Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Annals of neurology. 1995;38(1):51–7. doi: 10.1002/ana.410380111. PubMed PMID: 7611725.CrossRefPubMed
14.
Zurück zum Zitat Mittl RL, Jr., Yousem DM. Frequency of unexplained meningeal enhancement in the brain after lumbar puncture. AJNR Am J Neuroradiol. 1994;15(4):633–8. PubMed PMID: 8010262.PubMed Mittl RL, Jr., Yousem DM. Frequency of unexplained meningeal enhancement in the brain after lumbar puncture. AJNR Am J Neuroradiol. 1994;15(4):633–8. PubMed PMID: 8010262.PubMed
15.
Zurück zum Zitat Weller et al., „Hirnmetastasen und Meningeosis neoplastica“ 2015; in „Leitlinien für Diagnostik und Therapie in der Neurologie“; Diener, Hrsg. Weller et al., „Hirnmetastasen und Meningeosis neoplastica“ 2015; in „Leitlinien für Diagnostik und Therapie in der Neurologie“; Diener, Hrsg.
16.
Zurück zum Zitat Jung TY, Chung WK, Oh IJ. The prognostic significance of surgically treated hydrocephalus in leptomeningeal metastases. Clin Neurol Neurosurg. 2014;119:80–3. doi: 10.1016/j.clineuro.2014.01.023. PubMed PMID: 24635931.CrossRefPubMed Jung TY, Chung WK, Oh IJ. The prognostic significance of surgically treated hydrocephalus in leptomeningeal metastases. Clin Neurol Neurosurg. 2014;119:80–3. doi: 10.1016/j.clineuro.2014.01.023. PubMed PMID: 24635931.CrossRefPubMed
17.
Zurück zum Zitat Eralp Y, Saip P, Aydin Z, Berkman S, Topuz E. Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol. 2008;108(1):248–50. doi: 10.1016/j.ygyno.2007.09.024. PubMed PMID: 17961641.CrossRefPubMed Eralp Y, Saip P, Aydin Z, Berkman S, Topuz E. Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol. 2008;108(1):248–50. doi: 10.1016/j.ygyno.2007.09.024. PubMed PMID: 17961641.CrossRefPubMed
18.
Zurück zum Zitat Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology. 2005;64(9):1625–7. doi: 10.1212/01.WNL.0000160396.69050.DC. PubMed PMID: 15883329.CrossRefPubMed Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology. 2005;64(9):1625–7. doi: 10.1212/01.WNL.0000160396.69050.DC. PubMed PMID: 15883329.CrossRefPubMed
19.
Zurück zum Zitat Shapiro WR, Posner JB, Ushio Y, Chemik NL, Young DF. Treatment of meningeal neoplasms. Cancer Treat Rep. 1977;61(4):733–43. PubMed PMID: 577896.PubMed Shapiro WR, Posner JB, Ushio Y, Chemik NL, Young DF. Treatment of meningeal neoplasms. Cancer Treat Rep. 1977;61(4):733–43. PubMed PMID: 577896.PubMed
20.
Zurück zum Zitat Chamberlain MC, Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol. 1998;55(4):506–12. PubMed PMID: 9561978.CrossRefPubMed Chamberlain MC, Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol. 1998;55(4):506–12. PubMed PMID: 9561978.CrossRefPubMed
21.
Zurück zum Zitat Sandberg DI, Bilsky MH, Souweidane MM, Bzdil J, Gutin PH. Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery. 2000;47(1):49–54; discussion -5. PubMed PMID: 10917346.PubMed Sandberg DI, Bilsky MH, Souweidane MM, Bzdil J, Gutin PH. Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery. 2000;47(1):49–54; discussion -5. PubMed PMID: 10917346.PubMed
22.
Zurück zum Zitat Glantz MJ, Van Horn A, Fisher R, Chamberlain MC. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer. 2010;116(8):1947–52. doi: 10.1002/cncr.24921. PubMed PMID: 20151421.CrossRefPubMed Glantz MJ, Van Horn A, Fisher R, Chamberlain MC. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer. 2010;116(8):1947–52. doi: 10.1002/cncr.24921. PubMed PMID: 20151421.CrossRefPubMed
23.
Zurück zum Zitat Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394–402. PubMed PMID: 10589750.PubMed Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394–402. PubMed PMID: 10589750.PubMed
24.
Zurück zum Zitat Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. The New England journal of medicine. 1975;293(4):161–6. doi: 10.1056/NEJM197507242930402. PubMed PMID: 806016.CrossRefPubMed Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. The New England journal of medicine. 1975;293(4):161–6. doi: 10.1056/NEJM197507242930402. PubMed PMID: 806016.CrossRefPubMed
25.
Zurück zum Zitat Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25(11):1350–6. doi: 10.1200/JCO.2006.09.7311. PubMed PMID: 17312328.CrossRefPubMed Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25(11):1350–6. doi: 10.1200/JCO.2006.09.7311. PubMed PMID: 17312328.CrossRefPubMed
26.
Zurück zum Zitat Bousquet G, Darrouzain F, de Bazelaire C, Ternant D, Barranger E, Winterman S, et al. Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer. J Clin Oncol. 2014. doi: 10.1200/JCO.2012.44.8894. PubMed PMID: 25547506. Bousquet G, Darrouzain F, de Bazelaire C, Ternant D, Barranger E, Winterman S, et al. Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer. J Clin Oncol. 2014. doi: 10.1200/JCO.2012.44.8894. PubMed PMID: 25547506.
27.
Zurück zum Zitat Kadoch C, Li J, Wong VS, Chen L, Cha S, Munster P, et al. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res. 2014;20(4):1029–41. doi: 10.1158/1078-0432.CCR-13-0474. PubMed PMID: 24190981; PubMed Central PMCID: PMCPMC3944388.CrossRefPubMed Kadoch C, Li J, Wong VS, Chen L, Cha S, Munster P, et al. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res. 2014;20(4):1029–41. doi: 10.1158/1078-0432.CCR-13-0474. PubMed PMID: 24190981; PubMed Central PMCID: PMCPMC3944388.CrossRefPubMed
28.
Zurück zum Zitat Svenningsson A, Bergman J, Dring A, Vagberg M, Birgander R, Lindqvist T, et al. Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally. Neurol Neuroimmunol Neuroinflamm. 2015;2(2):e79. doi: 10.1212/NXI.0000000000000079. PubMed PMID: 25745637; PubMed Central PMCID: PMCPMC4345631.CrossRefPubMedPubMedCentral Svenningsson A, Bergman J, Dring A, Vagberg M, Birgander R, Lindqvist T, et al. Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally. Neurol Neuroimmunol Neuroinflamm. 2015;2(2):e79. doi: 10.1212/NXI.0000000000000079. PubMed PMID: 25745637; PubMed Central PMCID: PMCPMC4345631.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16(4):1561–7. PubMed PMID: 9552066.PubMed Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16(4):1561–7. PubMed PMID: 9552066.PubMed
30.
Zurück zum Zitat Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2013;8(8):1069–74. doi: 10.1097/JTO.0b013e318294c8e8. PubMed PMID: 23804027.CrossRef Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2013;8(8):1069–74. doi: 10.1097/JTO.0b013e318294c8e8. PubMed PMID: 23804027.CrossRef
31.
Zurück zum Zitat Schafer N, Scheffler B, Stuplich M, Schaub C, Kebir S, Rehkamper C, et al. Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol. 2013;31(11):e173–4. doi: 10.1200/JCO.2012.46.5773. PubMed PMID: 23460716.CrossRefPubMed Schafer N, Scheffler B, Stuplich M, Schaub C, Kebir S, Rehkamper C, et al. Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol. 2013;31(11):e173–4. doi: 10.1200/JCO.2012.46.5773. PubMed PMID: 23460716.CrossRefPubMed
32.
Zurück zum Zitat Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015;5(11):1164–77. doi: 10.1158/2159-8290.CD-15-0369. PubMed PMID: 26410082.CrossRefPubMedPubMedCentral Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015;5(11):1164–77. doi: 10.1158/2159-8290.CD-15-0369. PubMed PMID: 26410082.CrossRefPubMedPubMedCentral
Metadaten
Titel
Neuroonkologie
Meningeosis neoplastica
verfasst von
Prof. Dr. med. Michael Platten
Dr. med. Sarah Löw
Prof. Dr. med. Wolfgang Wick
Publikationsdatum
26.09.2016
Verlag
Springer Medizin
Erschienen in
InFo Neurologie + Psychiatrie / Ausgabe 9/2016
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI
https://doi.org/10.1007/s15005-016-1781-x

Weitere Artikel der Ausgabe 9/2016

InFo Neurologie + Psychiatrie 9/2016 Zur Ausgabe